drugset / Trial / NCT01204775

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

NCT01204775

Phase 3 Completed 26 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.

Timeline

Start
2011-06
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 2.5 mg Oral
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral
Background Metformin Small molecule 500 mg Oral